PFZ Pfizer

 
TIDMPFZ 
 
 

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2007 (AS AMENDED)

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES

REPRESENTING 1% OR MORE

 
1. 
KEY INFORMATION 
Name of person              Wellington Management Group LLP 
dealing 
Company dealt               Pfizer Inc. 
in 
Class of relevant security  Common Stock 
to which the 
dealings being disclosed 
relate 
Date                        18 November 2015 
of dealing 
2. INTERESTS AND 
SHORT POSITIONS 
(a)                         Interests and short positions (following dealing) in the class of  relevant security 
                            dealt in 
                            Long                                                                Short 
                            Number                                                       (%)    Number (%) 
(1)                         Relevant securities                       74,538,293 shares  1.21 % 
(2)                         Derivatives (other than options): 
(3)                         Options and agreements to purchase/sell: 
                            Total                                     74,538,293 shares  1.21 % 
(b)                         Interests and short positions in relevant securities of the  company, other than the 
                            class dealt in 
                            Long                                                                Short 
                            Number                                                       (%)    Number (%) 
(1)                         Relevant securities 
(2)                         Derivatives (other than options): 
(3)                         Options and agreements to purchase/sell: 
                            Total 
 
 
 
 
3.DEALINGS 
(a)   Purchases and sales 
Purchase/sell                                                              Number of relevant securities                                                                          Price per unit 
Sale                                                                       200 shares                                                                                             33.3100 USD 
Sale                                                                       1,000 shares                                                                                           33.2775 USD 
(b)   Derivatives transactions (other than options transactions) 
Product name                                                              Nature of transaction                                                   Number of relevant securities          Price per unit 
e.g. CFD 
(c)   Options transactions in respect of existing relevant securities 
(i)   Writing, selling, purchasing or varying 
Product namee.g. call option   Writing, purchasing, selling, varying etc. Number of securities to which the option relates  Exercise price         Type, e.g. American, European etc.   Expiry date  Option money paid/ received per unit 
(ii)  Exercising 
Product name                                                              Number of securities                                                      Exercise price per unit 
e.g. call option 
(d)   Other dealings (including subscribing for new securities) 
Nature of transaction                                                     Details                                                                   Price per unit (if applicable) 
 
 
 
4.OTHER INFORMATION 
Agreements, arrangements or understandings 
relating to options or  derivatives 
Full details of any agreement, 
arrangement or understanding 
between the person disclosing and any other 
person relating to the  voting rights of any relevant 
securities under any option referred  to on this 
form or relating to the voting 
rights or future  acquisition 
or disposal of any relevant securities 
to which any  derivative referred to on this form 
is referenced. If none, this  should be stated. 
None 
Is a Supplemental Form 8 attached?                      NO 
Date of disclosure                                      19 November 2015 
Contact name                                            Mark O'Brien 
Telephone number                                        44-20-7126-6310 
If a connected EFM, name of offeree/sell 
with which connected 
If a connected EFM, state nature of connection 
 
 
 
 

View source version on businesswire.com: http://www.businesswire.com/news/home/sell/en/

 
This information is provided by Business Wire 
 
 

(END) Dow Jones Newswires

November 19, 2015 10:09 ET (15:09 GMT)

Pfizer (LSE:PFZ)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

Pfizer (LSE:PFZ)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024